SCHEMBL1617573

SCHEMBL1617573

Cc1ncc(-c2ccc(N(S)C(N)=O)cc2)o1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 5/20 0.51
CA2 P00918 5/20 0.51
CA9 Q16790 5/20 0.51
CA1 P00915 4/20 0.51
HDAC4 P56524 2/20 0.43
NPC1 O15118 2/20 0.39
GAA P10253 2/20 0.39
RAB9A P51151 2/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
TP53 P04637 1/20 0.39
CYP1A2 P05177 1/20 0.39
GLA P06280 1/20 0.39
CYP2C9 P11712 1/20 0.39
HPGD P15428 1/20 0.39
NFKB1 P19838 1/20 0.39
CYP2C19 P33261 1/20 0.39
CASP3 P42574 1/20 0.39
NFKB2 Q00653 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1617655 0.82 RXRA (0.42) CA12CA2CA9CA1HDAC4
SCHEMBL1617365 0.74 NR1H4 (0.35) HSD17B10KMT2AMAPTPOLB
SCHEMBL15507350 0.72 CA12 (0.55) CA12CA2CA9CA1HDAC4
SCHEMBL725811 0.72 MAPT (0.32) ALDH1A1HPGDCYP2C19HSD17B10MAPT
SCHEMBL1360325 0.71 CA12 (0.62) CA12CA2CA9CA1HDAC4
SCHEMBL3566684 0.70 ALOX5 (0.44) RAB9AALDH1A1LMNASMN1; SMN2
SCHEMBL9284900 0.70 CA12 (0.61) CA12CA2CA9CA1HDAC4
SCHEMBL1889419 0.70 ADRA2A (0.41) KDM4ECYP1A2CYP2C19SMN1; SMN2KMT2A
SCHEMBL15986388 0.69 CA12 (0.49) CA12CA2CA9CA1HDAC4
SCHEMBL1617017 0.68 MAPT (0.47) LMNASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012030952-A3 REDUCING RIPPLE CURRENT IN A SWITCHED-MODE POWER CONVERTER EMPLOYING A BRIDGE TOPOLOGY TEXAS INSTRUMENTS INCORPORATED (US) 2012-05-10 WO disclosed
EP-2231629-B1 MODULATORS FOR AMYLOID BETA HOFFMANN LA ROCHE (CH) 2011-11-30 EP disclosed
US-7923450-B2 Modulators for amyloid beta HOFFMANN-LA ROCHE INC. (US) 2011-04-12 US disclosed
EP-2231629-A1 MODULATORS FOR AMYLOID BETA F. Hoffmann-La Roche AG (CH) 2010-09-29 EP disclosed
WO-2009087127-A1 MODULATORS FOR AMYLOID BETA F. HOFFMANN-LA ROCHE AG (CH) 2009-07-16 WO disclosed
US-20090181965-A1 MODULATORS FOR AMYLOID BETA F. HOFFMANN-LA ROCHE AG (CH) 2009-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181965-A1 MODULATORS FOR AMYLOID BETA APP, PSEN1, BACE1 CA12 4583/4885CA2 3929/4885CA9 4747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.